Track 04 of 14
Preventive Cardiology & Lipidology
Lp(a) lowering, PCSK9 trials, baxdrostat and residual risk.
Prevention is moving toward earlier and deeper lipid lowering, with VESALIUS-CV testing evolocumab in primary prevention, ESSENCE-TIMI 73 establishing olezarsen for severe hypertriglyceridemia, and the first wave of Lp(a)-lowering therapies (pelacarsen in Lp(a)HORIZON, olpasiran in OCEAN(a)-Outcomes, lepodisiran, muvalaplin) reading out. Hypertension is being reshaped by aldosterone synthase inhibition (BaxHTN baxdrostat), zilebesiran siRNA (KARDIA-3), and renal denervation re-emergence. The track integrates colchicine and IL-6 pathway inhibition for residual inflammatory risk, CAC and polygenic risk in ASCVD prediction, and ancestry-aware risk equations.
Focus areas
- Lp(a)-lowering: pelacarsen, olpasiran, lepodisiran, muvalaplin
- PCSK9 and inclisiran: VESALIUS-CV in primary prevention
- Olezarsen and APOC3-targeted hypertriglyceridemia therapy
- Hypertension: baxdrostat (BaxHTN) and zilebesiran (KARDIA-3)
- Colchicine and IL-6 inhibition: residual inflammatory risk
- CAC, polygenic risk, and ancestry-aware ASCVD prediction
- Renal denervation: post-approval real-world outcomes